Upstream Bio (UPB) Net Cash Flow (2023 - 2026)

Upstream Bio has reported Net Cash Flow for 4 years, with the latest figure at -$4.9 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 98.09% year-over-year to -$4.9 million; the trailing twelve-month figure through Mar 2026 stood at $25.4 million (down 36.46% YoY), and the FY2025 full-year result was -$224.3 million, down 174.71% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$4.9 million, down from $29.4 million in the prior quarter.
• The five-year high for Net Cash Flow was $292.9 million in Q4 2024, with the low at -$254.6 million in Q1 2025.
• Average Net Cash Flow over 4 years is $5.0 million, with a median of $411500.0 recorded in 2024.
• Year-over-year, Net Cash Flow surged 1463.48% in 2024 and tumbled 4584.41% in 2025.
• Tracing UPB's Net Cash Flow over 4 years: stood at -$21.5 million in 2023, then surged by 1463.48% to $292.9 million in 2024, then sank by 89.96% to $29.4 million in 2025, then plunged by 116.5% to -$4.9 million in 2026.
• The last three Net Cash Flow figures came in at -$4.9 million (Q1 2026), $29.4 million (Q4 2025), and $26.7 million (Q3 2025), per Business Quant data.

Peer Comparison